Related Experiment Video
Updated: Nov 22, 2025
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
GSDME: A Potential Ally in Cancer Detection and Treatment
J Ibrahim1, E De Schutter2, K Op de Beeck1
1Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43/6, 2650 Edegem, Antwerp, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium.
Gasdermin E (GSDME) executes pyroptosis, a cell death pathway crucial in cancer. Its role suggests GSDME is a promising biomarker for cancer diagnosis, monitoring, and treatment strategies.
Area of Science:
- Oncology
- Cellular Biology
- Biochemistry
Background:
- Gasdermin E (GSDME) is identified as a key executioner protein in caspase-3 mediated regulated pyroptosis.
- Pyroptosis is a critical inflammatory cell death pathway implicated in the pathogenesis and progression of various cancers.
Purpose of the Study:
- To investigate the role of Gasdermin E in cancer.
- To evaluate the potential of GSDME as a biomarker for cancer management.
Main Methods:
- Analysis of GSDME expression in cancer tissues.
- Assays to determine the pyroptotic activity mediated by GSDME.
- Correlation studies between GSDME levels and clinical outcomes.
Main Results:
- GSDME was found to be a significant mediator of pyroptosis in cancer cells.
- Elevated GSDME levels were observed in several types of cancer.
- GSDME expression correlated with patient prognosis and response to therapy.
Conclusions:
- Gasdermin E is a critical effector of pyroptosis with a significant role in cancer.
- GSDME holds considerable potential as a diagnostic and prognostic biomarker.
- Targeting GSDME-mediated pyroptosis may offer novel therapeutic strategies for cancer treatment.
